What is the official website of Novartis Italia ?

The official website of Novartis Italia is https://www.novartis.it/.

What is Novartis Italia's cybersecurity risk score?

Novartis Italia has an AI-generated cybersecurity risk score of 758 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Italia experienced?

According to Rankiteo, Novartis Italia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Italia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Italia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Italia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Italia is not certified under SOC 2 Type 1.

Does Novartis Italia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Italia does not hold a SOC 2 Type 2 certification.

Does Novartis Italia comply with GDPR ?

According to Rankiteo, Novartis Italia is not listed as GDPR compliant.

Does Novartis Italia have PCI DSS certification ?

According to Rankiteo, Novartis Italia does not currently maintain PCI DSS compliance.

Does Novartis Italia comply with HIPAA ?

According to Rankiteo, Novartis Italia is not compliant with HIPAA regulations.

Does Novartis Italia have ISO 27001 certification ?

According to Rankiteo,Novartis Italia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Italia operate in ?

Novartis Italia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Italia have ?

Novartis Italia employs approximately 506 people worldwide.

Does Novartis Italia own any subsidiaries ?

Novartis Italia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Italia have ?

Novartis Italia's official LinkedIn profile has approximately 104,037 followers.

What is the NAICS classification code for Novartis Italia ?

Novartis Italia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Italia have a Crunchbase profile ?

No, Novartis Italia does not have a profile on Crunchbase.

Does Novartis Italia have a LinkedIn profile ?

Yes, Novartis Italia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartisitalia.

How many cybersecurity incidents has Novartis Italia experienced ?

As of August 11, 2026, Rankiteo reports that Novartis Italia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Italia have ?

Novartis Italia has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Italia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Italia

Boost Score +25 with badge (5 left)

758

/1000

Fair

783

/1000

Fair

Novartis Italia Vendor Cyber Rating & Cyber Score

novartis.it

Add Your Compliance Badge

La nostra mission è scoprire nuovi modi per migliorare e prolungare la vita delle persone. Ci basiamo sull’ innovazione scientifica per affrontare le maggiori sfide in ambito sanitario: scopriamo e sviluppiamo trattamenti innovativi, identificando nuove modalità per far sì che raggiungano più persone possibili. Novartis ha sede a Basilea, in Svizzera. Le aziende del nostro Gruppo impiegano circa 125.000 collaboratori e i nostri prodotti sono disponibili in 155 Paesi in tutto il mondo. La capacità di attrarre, coltivare e mantenere i talenti è vitale per continuare a sviluppare prodotti innovativi in grado di offrire ai pazienti i migliori risultati. Leggi le linee guida della nostra community:

Novartis Italia A.I CyberSecurity Scoring

Scoring History

Novartis Italia

Novartis Italia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Italia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Italia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Italia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Italia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Italia in 2026.

Incident Types Novartis Italia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Italia in 2026.

Incident History - Novartis Italia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Italia Subsidiaries

Novartis Italia

Pharmaceutical Manufacturing

Website: https://www.novartis.it/

Company Size: 506

NovartisPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis DanmarkPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Loading…

Novartis Italia Similar Companies

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Loading…

NEWS

Novartis Italia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

June 06, 2024 07:00 AM

Novartis, Roche unit and others face Italy antitrust probe over eye drug

Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8718

SUMMARY

tls_opt_dtls_peer_connection_id_value_get() in subsys/net/lib/sockets/sockets_tls.c, which handles getsockopt(SOL_TLS, TLS_DTLS_PEER_CID_VALUE), passed the caller-supplied optval directly to mbedtls_ssl_get_peer_cid() without verifying the buffer was at least MBEDTLS_SSL_CID_OUT_LEN_MAX (default 32) bytes. mbedtls_ssl_get_peer_cid() copies the peer-negotiated DTLS Connection ID (length 1..MBEDTLS_SSL_CID_OUT_LEN_MAX) into that buffer without a destination-size parameter, so a caller-supplied optlen smaller than the CID causes a write of up to 31 bytes past the buffer end. In CONFIG_USERSPACE builds the getsockopt syscall verifier (z_vrfy_zsock_getsockopt) bounce-buffers the user's optval into a kernel allocation of exactly optlen bytes (k_usermode_alloc_from_copy -> z_thread_malloc), so an unprivileged user thread that passes a small optlen on a connected DTLS socket with Connection ID enabled induces a kernel-heap buffer overflow, with the overflowing content being the remote peer's CID. The defect requires CONFIG_MBEDTLS_SSL_DTLS_CONNECTION_ID, an established DTLS session with a negotiated peer CID, and (for the kernel-crossing case) CONFIG_USERSPACE. Introduced when the TLS_DTLS_CID option was added (v3.5.0). The fix rejects callers whose optlen is below MBEDTLS_SSL_CID_OUT_LEN_MAX with -EINVAL.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 8.4)

cvss3

Base Score: 8.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:C/C:N/I:H/A:H

Impact Score

5.8

Exploitability

REFERENCES

CVE-2026-48161

SUMMARY

react18-use is a React 19 use hook shim. Between 2026-05-19 01:07:01 and 2026-05-19 15:20:43, the default branch contained malicious commits 7b79148d1495a2505f9277da295a98cf176f4496 through 7b79148d1495a2505f9277da295a98cf176f4496 that executed remote attacker-controlled code on developer machines during `npm install`. The commits were removed by force-push, but local clones, forks, and direct-SHA URLs may still contain them, and `npm install` against an affected checkout will still execute the code today. The package was not published to npm. `src/install.js` was added and wired into the `postinstall` script. It fetched a JavaScript payload from an attacker-controlled HTTPS endpoint (configurable via an environment variable), disabled TLS verification, and evaluated the response as code with `require` available. Execution was deliberately skipped on CI and cloud/serverless environments, targeting developer workstations. The second-stage payload was attacker-hosted and cannot be reconstructed. Assume full compromise of anything reachable from a Node process with the user's permissions. Those who ran `npm install` against an affected checkout on a developer machine on or after 2026-05-19 01:07:01 should treat the machine as compromised, rotate every credential the machine could reach, audit account activity since 2026-05-19 01:07:01, and clean local clones.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/dai-shi/react18-use/security/advisories/GHSA-32xh-vg5f-64fm

CVE-2026-11812

SUMMARY

The UpdateHub management subsystem (subsys/mgmt/updatehub/updatehub.c) drives every update operation through a single file-scope ctx structure that holds the CoAP block context, payload buffer, status code, socket, and a one-element poll-fd array fds[1]. Access to ctx was not serialized, and prepare_fds() wrote ctx.fds[ctx.nfds] and incremented ctx.nfds with no bounds check. Two independent paths mutate ctx concurrently: the background autohandler running on the system workqueue, and user-triggered operations reached through the updatehub run shell command, direct API calls, or — since the operations are exposed as syscalls — userspace threads. When a second flow enters prepare_fds() while ctx.nfds is already 1, the write lands one element past the array; by struct layout it overlaps the adjacent ctx.sock/ctx.nfds members. More broadly, the unsynchronized sharing lets two flows interleave connection setup and teardown, double-closing a socket descriptor or scribbling the shared buffers. The result is corruption of the update subsystem's internal state and denial of service of the firmware-update path; the out-of-bounds write is contained within the ctx structure and there is no demonstrated path to memory outside it or to code execution. Triggering requires a local actor able to invoke update operations (or, with CONFIG_USERSPACE, an unprivileged userspace thread) and to win a timing race against the background handler; remote peers cannot control the race timing. The fix serializes the entry points with a mutex and adds a bounds check to prepare_fds().

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 2.5)

cvss3

Base Score: 2.5

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:L/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

REFERENCES

CVE-2026-11811

SUMMARY

The UpdateHub over-the-air update client's start_coap_client() in subsys/mgmt/updatehub/updatehub.c leaks the CoAP/DTLS socket descriptor on its connection-setup failure paths. The shared error: cleanup gated socket closing on a ret > 0 flag, but ret was set to -1 immediately after the socket was created, so when zsock_setsockopt() (DTLS) or zsock_connect() subsequently failed the gate was false and cleanup_connection() was never called. The open descriptor in the global ctx.sock was then overwritten by the next attempt, permanently leaking it from the socket / net_context pool until reboot. The failing setup path is reached every time the OTA client tries to contact the UpdateHub server and the connection cannot be established — driven automatically by the periodic autohandler() poll (and on demand via the updatehub_probe()/updatehub_update() API or the updatehub run shell command). The DTLS handshake/connect outcome is influenceable by a network or on-path attacker who drops, resets, or otherwise disrupts traffic to the server, and also fails naturally whenever the server is unreachable. Each failed attempt permanently leaks one descriptor; once the shared socket pool is exhausted, networking degrades device-wide until the device is rebooted, a denial-of-service condition. Severity is low because the leak rate is bounded by the configured OTA poll interval (default once per 24 hours), the effect is gradual and recovered by reboot, and only builds with the UpdateHub client enabled are affected. There is no memory-corruption, information-disclosure, or authentication impact.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2025-30241

SUMMARY

Certain web interface components in affected TP-Link Aginet devices do not validate and sanitize user-supplied input properly before passing it to system-level command execution functions. An authenticated adjacent attacker may inject specially crafted input to execute arbitrary operation system commands with elevated privileges. Successful exploitation may allow execution of arbitrary system commands, potentially leading to full device compromise.

Published

Date2026-08-10

Updated

Date2026-08-10

RISK INFORMATION (Score: )

cvss4

Base Score: 8.6

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://www.tp-link.com/us/support/faq/5239/

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…